Humacyte, Inc. (HUMA) stock
HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.50−0.04 (-7.27%)
Close on Nov 17, 2026Market cap $139.18MP/E –Yield –
Humacyte shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Humacyte's shares outstanding was 234M at Jun 30, 2026. For fiscal 2025 it was 158M, up 33.5% from the year before. The highest annual figure on record is 158M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 158M | +33.5% |
| FY2024 | Dec 31, 2024 | 118M | +14.6% |
| FY2023 | Dec 31, 2023 | 103M | +0.4% |
| FY2022 | Dec 31, 2022 | 103M | +157.8% |
| FY2021 | Dec 31, 2021 | 40M | +593.2% |
| FY2020 | Dec 31, 2020 | 6M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 234M | +50.7% |
| Q1 FY2026 | Mar 31, 2026 | 198M | +50.2% |
| Q4 FY2025 | Dec 31, 2025 | 187M | +47.3% |
| Q3 FY2025 | Sep 30, 2025 | 158M | +32.6% |
| Q2 FY2025 | Jun 30, 2025 | 155M | +30.4% |
| Q1 FY2025 | Mar 31, 2025 | 132M | +21.7% |
| Q4 FY2024 | Dec 31, 2024 | 127M | +22.6% |
| Q3 FY2024 | Sep 30, 2024 | 119M | +15.4% |
| Q2 FY2024 | Jun 30, 2024 | 119M | +15.3% |
| Q1 FY2024 | Mar 31, 2024 | 108M | +4.8% |
| Q4 FY2023 | Dec 31, 2023 | 104M | +0.4% |
| Q3 FY2023 | Sep 30, 2023 | 103M | +0.4% |
| Q2 FY2023 | Jun 30, 2023 | 103M | -0.5% |
| Q1 FY2023 | Mar 31, 2023 | 103M | +0.3% |
| Q4 FY2022 | Dec 31, 2022 | 103M | +134.7% |
| Q3 FY2022 | Sep 30, 2022 | 103M | +1634.1% |
| Q2 FY2022 | Jun 30, 2022 | 104M | +1668.7% |
| Q1 FY2022 | Mar 31, 2022 | 103M | +1677.0% |
| Q3 FY2021 | Sep 30, 2021 | 44M | +659.3% |
| Q2 FY2021 | Jun 30, 2021 | 6M | – |
| Q1 FY2021 | Mar 31, 2021 | 6M | – |
| Q4 FY2020 | Dec 31, 2020 | 6M | – |
| Q3 FY2020 | Sep 30, 2020 | 6M | – |
See a number that looks wrong?